Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Applied Molecular Transport Inc (AMTI) USD0.0001

Sell:$28.34 Buy:$28.63 Change: $1.26 (4.60%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.26 (4.60%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.26 (4.60%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform including its product candidate, AMT-101, an oral GI-selective rhIL-10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of rhIL-22. The Company’s technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics, with development-stage drugs.

Contact details

1 Tower Place, Suite 850
United States
+1 (650) 3920420

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.05 billion
Shares in issue:
38.42 million
United States
US dollar

Key personnel

  • Tahir Mahmood
    Chief Executive Officer, Co-Founder, Director
  • Randall Mrsny
    Co-Founder, Chief Scientific Officer, Director
  • Shawn Cross
    Chief Financial Officer
  • Brandon Hants
    Senior Vice President - Finance and Business Operations
  • Derek Maclean
    Senior Vice President - Pharmaceutical Sciences
  • Chuck Olson
    Senior Vice President - Operations
  • Douglas Rich
    Chief Technical Officer
  • Andy Whitney
    Vice President - Preclinical Development and Translational Science
  • Elizabeth Bhatt
    Chief Business and Strategy Officer
  • Bittoo Kanwar
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.